Etusivu › Ei-pienisoluinen keuhkosyöpä › Florida › Tampa
Ei-pienisoluinen keuhkosyöpä-kliiniset tutkimukset kaupungissa Tampa, FL
51 Ei-pienisoluinen keuhkosyöpä-tutkimusta hakee osallistujia kohteissa kaupungissa Tampa ja sen lähialueilla (noin 30 mailin säteellä). Avaa tutkimus nähdäksesi kelpoisuusehdot ja yhteydenottotiedot.
Virallinen tutkimusteksti (englanniksi)
Etsitkö osallistujia tutkimukseesi? Nosta se sivun kärkeen – $99 / 30 päivää →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Osallistujahaku käynnissäVaihe 2/3
- Moffitt Cancer Center /ID# 276785, Tampa
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Osallistujahaku käynnissäVaihe 3
- Moffitt Cancer Center, Tampa
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Osallistujahaku käynnissäVaihe 1
- Exelixis Clinical Site #8, Tampa
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Osallistujahaku käynnissäVaihe 3
- Moffitt Cancer Center-International Plaza, Tampa
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- ja 1 lisää
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Osallistujahaku käynnissäVaihe 1
- Moffitt Cancer Center, Tampa
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Osallistujahaku käynnissäVaihe 2
- Moffit Cancer Centre, Tampa
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Osallistujahaku käynnissäVaihe 1
- ALX Center 7, Tampa
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Osallistujahaku käynnissäVaihe 3
- H Lee Moffitt Cancer Center and Research Institute, Tampa
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Osallistujahaku käynnissäHavainnoiva tutkimus
- Moffitt Cancer Center, Tampa
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Osallistujahaku käynnissäVaihe 3
- Florida Cancer Specialists, Tampa
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Osallistujahaku käynnissäVaihe 2
- Moffitt Cancer Center, Tampa
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Osallistujahaku käynnissäVaihe 3
- Moffitt Cancer Center, Tampa
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Osallistujahaku käynnissäVaihe 3
- H. Lee Moffitt Cancer Center & Research Institute, Tampa
- Local Institution - 0647, Tampa
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Osallistujahaku käynnissäVaihe 2/3
- H. Lee Moffit Cancer center and research institute, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center and Research Institute, Tampa
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Osallistujahaku käynnissäVaihe 2
- Moffitt Cancer Center, Tampa
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center, Tampa
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Osallistujahaku käynnissäVaihe 1
- Moffitt Cancer Center, Tampa
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Osallistujahaku käynnissäVaihe 1
- Moffitt Cancer Center, Tampa
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Osallistujahaku käynnissäVaihe 2/3
- James A. Haley Veterans Hospital, Tampa
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Osallistujahaku käynnissäVaihe 2
- Moffitt Cancer Center, Tampa
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Osallistujahaku käynnissäVaihe 2
- Moffitt Cancer Center, Tampa
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Osallistujahaku käynnissäVaihe 3
- Research Site, Tampa
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center, Tampa
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Osallistujahaku käynnissäVaihe 1
- Moffitt Cancer Center, Tampa
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Osallistujahaku käynnissäVaihe 2
- Moffitt Cancer Center and Research Institute, Tampa
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Osallistujahaku käynnissäVaihe 3
- Moffitt Cancer Center, Tampa
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Osallistujahaku käynnissäVaihe 1/2
- Moffit Cancer Center, Tampa
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center, Tampa
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Osallistujahaku käynnissäVaihe 3
- Moffit Cancer Center, Tampa
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Osallistujahaku käynnissäVaihe 1/2
- H Lee Moffitt Cancer Center and Research Institute, Tampa
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Osallistujahaku käynnissäVaihe 2
- H Lee Moffitt Cancer Center and Research Institute, Tampa
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Osallistujahaku käynnissäVaihe 3
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center, Tampa
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Osallistujahaku käynnissäVaihe 1
- Moffitt Cancer Center, Tampa
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center and Research Institute, Tampa
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Osallistujahaku käynnissäVaihe 2
- Moffitt Cancer Center, Tampa
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Osallistujahaku käynnissäVaihe 1
- Lee Moffitt Cancer Center, Tampa
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Osallistujahaku käynnissäVaihe 1
- Moffitt Cancer Center, Tampa
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center, Tampa
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Osallistujahaku käynnissäVaihe 2/3
- Moffitt Cancer Center, Tampa
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Osallistujahaku käynnissäVaihe 2
- Moffit Cancer Center, Tampa
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Osallistujahaku käynnissäVaihe 2
- Moffitt Cancer Center, Tampa
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Osallistujahaku käynnissäVaihe 2
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Osallistujahaku käynnissäVaihe 2
- Moffitt Cancer Center, Tampa
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Osallistujahaku käynnissäHavainnoiva tutkimus
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Osallistujahaku käynnissäHavainnoiva tutkimus
- Massive Bio SYNERGY-AI site, Tampa
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center, Tampa
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Osallistujahaku käynnissäVaihe 1/2
- Moffitt Cancer Center, Tampa
Ei-pienisoluinen keuhkosyöpä-tutkimukset muissa kaupungeissa
- Houston, TX145 tutkimusta
- New York City, NY121 tutkimusta
- Arlington, VA104 tutkimusta
- Nashville, TN97 tutkimusta
- Boston, MA90 tutkimusta
- Los Angeles, CA87 tutkimusta
- St. Louis, MO73 tutkimusta
- Chicago, IL61 tutkimusta
- Baltimore, MD60 tutkimusta
- San Antonio, TX59 tutkimusta
- Columbus, OH57 tutkimusta
- Washington, DC55 tutkimusta
Muut tutkimukset kaupungissa Tampa
- Rintasyöpä43 tutkimusta
- Syöpä (kaikki tyypit)39 tutkimusta
- Paksu- ja peräsuolen syöpä34 tutkimusta
- Akuutti myelooinen leukemia29 tutkimusta
- Etäpesäkkeinen syöpä29 tutkimusta
- Keuhkosyöpä29 tutkimusta
- Haimasyöpä26 tutkimusta
- Munasarjasyöpä21 tutkimusta
- Melanooma19 tutkimusta
- Myelodysplastiset syndroomat19 tutkimusta
- Eturauhassyöpä18 tutkimusta
- Sydämen vajaatoiminta18 tutkimusta
Lähde: ClinicalTrials.gov, tiedot haettu 6.10.2026. Jokaisella tutkimuksella on omat kelpoisuusehdot; tutkimusryhmä päättää, ketkä voivat osallistua.